Nohla Therapeutics is a biotechnology startup founded in 2015, dedicated to developing off-the-shelf cellular therapies for patients with critical diseases. Their primary product, a universal donor cell therapy, aims to address hematopoietic recovery and chemotherapy-induced neutropenia. What sets Nohla apart is its unique umbilical cord blood expansion platform which serves as the foundation for their current and future products. This innovative approach was developed at the Fred Hutchinson Cancer Research Center. Nohla Therapeutics is positioning itself as a key player in the critical disease treatment space, leveraging its cutting-edge technology and product pipeline. As a healthcare and wellness-focused company, Nohla is well poised to capture a significant market share in the coming years. Their dedication to providing effective and accessible therapies aligns with the growing demand for improved medical treatments. Even though specific details about their headquarter location and previous investments are not provided, Nohla’s focus on developing novel therapies makes it an intriguing prospect for potential venture capital investments.
There is no investment information
No recent news or press coverage available for Nohla Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.